NICE won't endorse NHS coverage of Bristol's RA drug Orencia

03/29/2011 | Wall Street Journal, The

The U.K. National Institute for Health and Clinical Excellence said Bristol-Myers Squibb's Orencia, or abatacept, is not cost-effective for National Health Service use as second-line treatment for adults with moderate to severe rheumatoid arthritis who did not respond to standard nonbiologic medicines. The agency said it already endorsed coverage of several other RA drugs.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC